DaVita Venture Group
DaVita Venture Group, founded in 2020 and based in Denver, Colorado, serves as the investment arm of DaVita Inc. It focuses on partnering with healthcare innovators to enhance the lives of patients with kidney disease. The group aims to invest in, develop, and launch products and solutions that improve patient care, particularly in areas such as digital health, pharmaceuticals, and care delivery models. By targeting early-stage and later-stage companies, DaVita Venture Group seeks to support advancements that improve clinical outcomes, enhance patient experiences, and expand access to care, particularly through digital innovations and value-based treatment approaches.
Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.
Heartbeat Health, Inc. is a New York-based company that specializes in cardiology services. Established in 2017, it provides a range of offerings, including web-based real-time consulting and virtual physician consultations, along with follow-up services. The company aims to address cardiovascular health by screening, diagnosing, tracking, and managing cardiovascular risk and disease, leveraging a multidisciplinary team of doctors, designers, and engineers committed to improving heart health outcomes.
Developer of a urine-based diagnostic tool designed to predict and prevent the progression of kidney disease. The company's tool permits quantitative measurement of biomarkers for the early detection and lifetime monitoring of kidney disease, enabling physicians to detect acute rejection of kidney transplants noninvasively.
ConsejoSano offers multicultural engagement and navigation solutions for health plans, providers, states to help guide culturally diverse populations through the complexities of the health care system and drive improved performance, outcomes and satisfaction.
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.